Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92869 | 1.00 | UCHL1 (0.49) | UCHL1HSD17B10NR1H2CHRM2CHRM1 | |
| SCHEMBL3829673 | 1.00 | UCHL1 (0.49) | UCHL1HSD17B10NR1H2CHRM2CHRM1 | |
| SCHEMBL1582803 | 1.00 | UCHL1 (0.49) | UCHL1HSD17B10NR1H2CHRM2CHRM1 | |
| SCHEMBL17783113 | 1.00 | UCHL1 (0.49) | UCHL1HSD17B10NR1H2CHRM2CHRM1 | |
| SCHEMBL5480506 | 1.00 | UCHL1 (0.49) | UCHL1HSD17B10NR1H2CHRM2CHRM1 | |
| SCHEMBL8269128 | 1.00 | UCHL1 (0.49) | UCHL1HSD17B10NR1H2CHRM2CHRM1 | |
| SCHEMBL5478578 | 1.00 | UCHL1 (0.49) | UCHL1HSD17B10NR1H2CHRM2CHRM1 | |
| SCHEMBL1270226 | 1.00 | UCHL1 (0.49) | UCHL1HSD17B10NR1H2CHRM2CHRM1 | |
| SCHEMBL18577435 | 0.88 | HSD17B10 (0.41) | UCHL1HSD17B10NR1H2CHRM2CHRM1 | |
| SCHEMBL29015380 | 0.88 | HSD17B10 (0.41) | UCHL1HSD17B10NR1H2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4615847-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4608509-A1 | NEW INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-09-03 | — | — | EP | disclosed |
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2025-05-22 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| CN-114591212-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2024-10-31 | — | — | US | disclosed |
| EP-4452964-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2024-10-30 | — | — | EP | disclosed |
| EP-3800186-B1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LTD (GB) | 2024-10-02 | — | — | EP | disclosed |
| WO-1998050030-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
| EP-0618809-B1 | BRADYKININ TYPE PEPTIDES | SCIOS NOVA INC (US) | 1998-08-19 | — | — | EP | disclosed |
| US-5385889-A | Substitution of L-proline at the 7-position of the peptide hormone with a D-configuration hydroxyproline ether or thioether converts agonist into antagonist | SCIOS NOVA INC. (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0618810-A4 | BRADYKININ ANTAGONIST PEPTIDES. | SCIOS NOVA INC (US) | 1994-12-07 | — | — | EP | disclosed |
| EP-0618810-A1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| WO-1992018156-A1 | BRADYKININ ANTAGONIST PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | disclosed |
| EP-0053902-B1 | PHOSPHINYLALKANOYL SUBSTITUTED PROLINES | E.R. Squibb & Sons, Inc. (US) | 1985-04-03 | — | — | EP | disclosed |
| US-4384123-A | Phosphinylalkanoyl substituted prolines | E. R. SQUIBB & SONS, INC. (US) | 1983-05-17 | — | — | US | disclosed |
| US-4337201-A | Phosphinylalkanoyl substituted prolines | E. R. SQUIBB & SONS, INC. (US) | 1982-06-29 | — | — | US | disclosed |
| EP-0053902-A1 | Phosphinylalkanoyl substituted prolines | E.R. Squibb & Sons, Inc. (US) | 1982-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | NRAS, KRAS, RB1 | UCHL1 3057/4885HSD17B10 3735/4885NR1H2 1464/4885 |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | UCHL1 4354/4885HSD17B10 1160/4885NR1H2 3543/4885 |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | SUMO1, SUMO3, SUMO2 | UCHL1 36/4885HSD17B10 2345/4885NR1H2 3556/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | UCHL1 60/4885HSD17B10 1332/4885NR1H2 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.